Silence Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Silence Therapeutics generated cash of $1,672,000, which is less than the previous year. Cash used in financing activities reached the amount of $31,612,000 last year. Net change in cash is therefore -$6,386,000.
Cash Flow
| 2011 | -5.11M | -243K | 5.51M |
|---|---|---|---|
| 2012 | -4.87M | -133K | 10.24M |
| 2013 | -6.75M | -5.09M | 18.78M |
| 2014 | -9.45M | -201K | 10.84M |
| 2015 | -8.25M | 4.32M | 39.15M |
| 2016 | -10.06M | -4.67M | -101K |
| 2017 | -9.59M | 13.01M | 48K |
| 2018 | -16.76M | -4.83M | 341K |
| 2019 | 1.72M | -15.01M | 5.27M |
| 2020 | 1.67M | -41.25M | 31.61M |
SLN.L Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 27.03M | 21.49M | 42.74M | 39.01M | 51.90M | 16.85M | 15.89M | 8.90M | 3.68M | 3.56M |
Operating activities | ||||||||||
Net income | -32.54M | -19.58M | -18.41M | -1.61M | -8.44M | -6.64M | -11.08M | -9.00M | -26.28M | -5.73M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 428K | 482K | 399K | 433K | 310K | 182K | 332K | 297K | 252K | 305K |
Stock-based compensation expense | 2.70M | 584K | 681K | 638K | 475K | 777K | 1.12M | 1.58M | 656K | 121K |
| Deferred income tax benefit | 2.70M | 584K | 681K | 638K | 475K | 777K | 1.12M | 1.58M | 656K | 121K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27K |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | 1.67M | 1.72M | -16.76M | -9.59M | -10.06M | -8.25M | -9.45M | -6.75M | -4.87M | -5.11M |
Investing activities | ||||||||||
Purchases Of Investments | -40.04M | -15M | -5M | -4.92M | -4.29M | 0 | 0 | -5M | 0 | -6K |
Investments In Property Plant And Equipment | -794K | -9K | -188K | -173K | -537K | -850K | -338K | -138K | -202K | -274K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -41.25M | -15.01M | -4.83M | 13.01M | -4.67M | 4.32M | -201K | -5.09M | -133K | -243K |
Financing activities | ||||||||||
Common Stock Issued | 31.61M | 5.27M | 341K | 48K | 0 | 39.15M | 10.84M | 18.78M | 10.24M | 5.51M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -101K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 31.61M | 5.27M | 341K | 48K | -101K | 39.15M | 10.84M | 18.78M | 10.24M | 5.51M |
Net Change In Cash | -6.38M | -7.97M | -21.25M | 3.73M | -12.89M | 35.05M | 967K | 6.98M | 5.22M | 121K |
Cash at end of period | 20.64M | 13.51M | 21.49M | 42.74M | 39.01M | 51.90M | 16.85M | 15.89M | 8.90M | 3.68M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |